Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Reiss

Showing results (261-270 of 270) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 270 results.
Bioorganic & Medicinal Chemistry Letters|May 26, 1999
Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potencyP D Williams, M G Bock, B E Evans, et al.
Journal of Medicinal Chemistry|June 17, 1998
Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridinesI M Bell, J M Erb, R M Freidinger, et al.
European Journal of Pharmacology|September 15, 2004
Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonistRichard W Ransom, Charles M Harrell, Duane R Reiss, et al.
ACS Chemical Neuroscience|July 21, 2012
Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonistsMark E Layton, Michael J Kelly, Kevin J Rodzinak, et al.
Chemmedchem|May 7, 2009
Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in ratsDavid B Whitman, Christopher D Cox, Michael J Breslin, et al.
Lancet (London, England)|November 18, 2021
Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USASaad B Omer, Regina M Benjamin, Noel T Brewer, et al.
Journal of Medicinal Chemistry|January 19, 2007
Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonistsScott D Kuduk, Christina N Di Marco, Ronald K Chang, et al.
Chemmedchem|February 7, 2012
Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting propertiesPaul J Coleman, John D Schreier, Christopher D Cox, et al.
Journal of Medicinal Chemistry|June 23, 2010
Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomniaChristopher D Cox, Michael J Breslin, David B Whitman, et al.
The Annals of Thoracic Surgery|January 8, 2013
Aortic valve and ascending aorta guidelines for management and quality measures: executive summaryLars G Svensson, David H Adams, Robert O Bonow, et al.
Pageof 27

Showing results (261-270 of 270) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 270 results.
Bioorganic & Medicinal Chemistry Letters|May 26, 1999
Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potencyP D Williams, M G Bock, B E Evans, et al.
Journal of Medicinal Chemistry|June 17, 1998
Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridinesI M Bell, J M Erb, R M Freidinger, et al.
European Journal of Pharmacology|September 15, 2004
Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonistRichard W Ransom, Charles M Harrell, Duane R Reiss, et al.
ACS Chemical Neuroscience|July 21, 2012
Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonistsMark E Layton, Michael J Kelly, Kevin J Rodzinak, et al.
Chemmedchem|May 7, 2009
Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in ratsDavid B Whitman, Christopher D Cox, Michael J Breslin, et al.
Lancet (London, England)|November 18, 2021
Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USASaad B Omer, Regina M Benjamin, Noel T Brewer, et al.
Journal of Medicinal Chemistry|January 19, 2007
Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonistsScott D Kuduk, Christina N Di Marco, Ronald K Chang, et al.
Chemmedchem|February 7, 2012
Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting propertiesPaul J Coleman, John D Schreier, Christopher D Cox, et al.
Journal of Medicinal Chemistry|June 23, 2010
Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomniaChristopher D Cox, Michael J Breslin, David B Whitman, et al.
The Annals of Thoracic Surgery|January 8, 2013
Aortic valve and ascending aorta guidelines for management and quality measures: executive summaryLars G Svensson, David H Adams, Robert O Bonow, et al.
Pageof 27